Patents by Inventor Masakuni KURONO
Masakuni KURONO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11919917Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.Type: GrantFiled: August 6, 2021Date of Patent: March 5, 2024Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Ryosuke Hanada, Masaya Kokubo, Masakuni Kurono, Kenichi Kouda, Hiroshi Hagiya
-
Publication number: 20230339992Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.Type: ApplicationFiled: June 22, 2023Publication date: October 26, 2023Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Ryosuke HANADA, Masaya KOKUBO, Masakuni KURONO, Kenichi KOUDA, Hiroshi HAGIYA
-
Publication number: 20230151024Abstract: The object of the present invention is to provide a drug containing a compound having an agonistic activity to STING as an active ingredient. As a result of intensive studies by the inventors of the present invention, the compound represented by the following general formula (I-1) [in the formula, all symbols represent the same meanings as described in the present specification.] or the like, having the agonistic activity to STING, as a substance capable of solving such objects, and this invention was completed. Since the compound represented by the general formula (I-1) or the like of the present invention has the agonistic activity to STING, it can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.Type: ApplicationFiled: April 10, 2020Publication date: May 18, 2023Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Ryosuke HANADA, Masaya KOKUBO, Masakuni KURONO, Kenichi KOUDA, Hiroshi HAGIYA
-
Patent number: 11512087Abstract: The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.Type: GrantFiled: June 27, 2019Date of Patent: November 29, 2022Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Hiroshi Tokura, Masakuni Kurono, Yoshinori Nomura, Shingo Hotta
-
Publication number: 20220306640Abstract: A compound of formula (I-a): wherein the symbols are defined in the specification, and which has a strong DDR1 inhibitory activity, and can be a therapeutic agent for DDR1-related diseases, for example, a cancer, a kidney disease, a cardiovascular disease, a central nervous system disease, or fibrosis.Type: ApplicationFiled: September 4, 2020Publication date: September 29, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Yota NISHIOKA, Masakuni KURONO, Rena NISHIZAWA, Balachandra BANDODKAR, Xuechao GAO, Zhilong WAN, Ranran LV, Kevin DOYLE, Michael GOLDSMITH
-
Publication number: 20210363166Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.Type: ApplicationFiled: August 6, 2021Publication date: November 25, 2021Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Ryosuke HANADA, Masaya KOKUBO, Masakuni KURONO, Kenichi KOUDA, Hiroshi HAGIYA
-
Patent number: 11130773Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.Type: GrantFiled: October 10, 2019Date of Patent: September 28, 2021Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Ryosuke Hanada, Masaya Kokubo, Masakuni Kurono, Kenichi Kouda, Hiroshi Hagiya
-
Publication number: 20210253615Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.Type: ApplicationFiled: October 10, 2019Publication date: August 19, 2021Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Ryosuke HANADA, Masaya KOKUBO, Masakuni KURONO, Kenichi KOUDA, Hiroshi HAGIYA
-
Patent number: 11052091Abstract: The present invention relates to a Brk inhibitory compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug of any of these.Type: GrantFiled: December 20, 2017Date of Patent: July 6, 2021Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Masakuni Kurono, Atsushi Yoshida, Shingo Hotta
-
Publication number: 20200000810Abstract: The present invention relates to a Brk inhibitory compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug of any of these.Type: ApplicationFiled: December 20, 2017Publication date: January 2, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Masakuni KURONO, Atsushi YOSHIDA, Shingo HOTTA
-
Publication number: 20190315756Abstract: The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.Type: ApplicationFiled: June 27, 2019Publication date: October 17, 2019Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Hiroshi TOKURA, Masakuni KURONO, Yoshinori NOMURA, Shingo HOTTA
-
Patent number: 10377759Abstract: The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.Type: GrantFiled: June 21, 2016Date of Patent: August 13, 2019Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Hiroshi Tokura, Masakuni Kurono, Yoshinori Nomura, Shingo Hotta
-
Publication number: 20180186800Abstract: The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.Type: ApplicationFiled: June 21, 2016Publication date: July 5, 2018Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Hiroshi TOKURA, Masakuni KURONO, Yoshinori NOMURA, Shingo HOTTA
-
Publication number: 20180089363Abstract: A method for extracting a lead compound from a plurality of compounds against a drug discovery target, includes the steps of creating a scatter diagram for a plurality of compounds by disposing symbols representing the compounds according to a plurality of features of the compounds and extracting a lead compound from the compounds represented by the symbols disposed in a predetermined region of the scatter diagram. The locations of the symbols to be disposed on the scatter diagram are determined according to first and second features (for example, selectivity and activity) of the respective compounds, and attributes (for example, color and size) of the symbols are determined according to third and fourth features (for example, molecular weight and ligand efficiency) of the respective compounds.Type: ApplicationFiled: April 21, 2016Publication date: March 29, 2018Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Masakuni KURONO, Hiromu EGASHIRA, Jun TAKEUCHI